Novartis and Sawai end Japan ciclosporin case
This article was originally published in Scrip
Executive Summary
Novartisand the Japanese generics company Sawai have agreed to end litigation relating to the immunosuppressant ciclosporin. The Swiss firm instigated legal action against Sawai in the Tokyo district court in December 2006, claiming the company's generic ciclosporin capsules infringed patents for its original branded product Neoral. Without disclosing terms, Sawai said that the action had now been halted and that sales of its product would continue unaffected.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.